Myeloid Leukemia of Down Syndrome

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myeloid leukemia of Down syndrome (ML-DS) is a distinct entity with unique features.
• Individuals with Down syndrome (DS) have trisomy 21, affecting hematopoiesis and increasing leukemia risk.
• Transient abnormal myelopoiesis (TAM) is a preleukemic phase preceding ML-DS in 5-10% of neonates with DS.

Purpose of the Study:

• To review recent advances in cytogenetics and molecular mechanisms of TAM and ML-DS.
• To discuss the integration of these advances in risk stratification and targeted management of ML-DS.

Main Methods:

• Review of current literature on ML-DS and TAM.
• Analysis of cytogenetic and molecular data related to chromosome 21 and GATA1 mutations.

Main Results:

• ML-DS is characterized by trisomy 21 and acquired GATA1 mutations, conferring a growth advantage to leukemic cells.
• While most TAM cases resolve spontaneously, 20-30% progress to ML-DS by age 4.
• ML-DS blasts exhibit hypersensitivity to chemotherapy, necessitating risk-adapted treatment due to increased toxicity.

Conclusions:

• Understanding the evolution of TAM and ML-DS is crucial for improving risk stratification.
• Targeted management strategies are essential for optimizing treatment outcomes in children with ML-DS.
• Advances in understanding genetic and molecular underpinnings guide therapeutic development for ML-DS.